argenx SE (NAS:ARGX)
$ 356.01 -3.47 (-0.97%) Market Cap: 21.90 Bil Enterprise Value: 18.74 Bil PE Ratio: 0 PB Ratio: 5.39 GF Score: 74/100

argenx SE Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-09-2023 09:00 AM Transcript

Jan 09, 2023 / 05:00PM GMT
Release Date Price: $372.96 (-0.76%)
James Daniel Gordon
JPMorgan Chase & Co, Research Division - Senior Analyst

Great. Good morning. I'm James Gordon, JPMorgan European pharma and biotech analyst. And today, I've got the pleasure of introducing the argenx presentation. And you're going to hear from argenx CEO, Tim Van Hauwermeiren. And then we're going to have the Q&A in this room as well. So 20 minutes of presentation and then 20 minutes of Q&A. And if you've got any questions, you can also register those questions, and I can read them off the iPad or you'll be able to put your hand up, and we'll do live questions. So with that said, thanks a lot for joining us today, Tim.

Timothy Van Hauwermeiren
argenx SE - CEO & Executive Director

Thank you, James. And a very warm welcome to all of you, ladies and gentlemen. It's exactly 1 year ago since we launched VYVGART here in the United States. And since that day, very powerful patient anecdotes are reaching us at argenx. And I thought I would start today by sharing 2 very recent stories of our VYVGART patients.

The first

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot